1. Home
  2. MDV vs TLSA Comparison

MDV vs TLSA Comparison

Compare MDV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modiv Industrial Inc. Class C

MDV

Modiv Industrial Inc. Class C

HOLD

Current Price

$14.70

Market Cap

159.4M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.36

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDV
TLSA
Founded
2015
2013
Country
United States
United Kingdom
Employees
12
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.4M
155.2M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MDV
TLSA
Price
$14.70
$1.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
49.7K
104.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.62
$0.73
52 Week High
$17.15
$2.60

Technical Indicators

Market Signals
Indicator
MDV
TLSA
Relative Strength Index (RSI) 41.67 46.13
Support Level $14.11 $1.29
Resistance Level $14.96 $1.61
Average True Range (ATR) 0.40 0.10
MACD -0.09 -0.01
Stochastic Oscillator 13.72 37.84

Price Performance

Historical Comparison
MDV
TLSA

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: